

**510(k) Summary**

OCT 26 2007

This summary of 510(k)-safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Date Prepared: July 20, 2007

510(k) number: K072063

**Applicant Information:**

KFx Medical  
5145 Avenida Encinas  
Suite C  
Carlsbad, CA 92008

**Contact Person**

M. D. Heaven  
Phone number: 619 270 8478  
FAX number: 760 602 9252  
e-mail: malcolm.heaven@kfxmed.com

**Device Information:**

Trade Name: KFx Tissue Fixation System and Accessories  
Classification: Class II  
Classification Name: Screw, Fastener, Fixation, Non-degradable, Soft Tissue.

**Physical Description:**

The KFx Tissue Fixation System consists of

- KFx Nail Bone Anchor with two suture leads, mounted to a single use handle
- KFx Suture Lock Bone Anchor mounted to a single use handle
- Optional KFx Targeting Grasper
- Optional Suture Management Device(s)
- Optional Screw Removal device
- Optional Starter Awl

**Intended Use:**

The KFx Tissue Fixation System and optional accessories are intended for the fixation of soft tissue to bone in the shoulder, foot/ankle, knee, hand/wrist, and elbow.

Specifically:

Shoulder: Bankart lesion repairs, SLAP lesion repairs, acromio-clavicular separation repairs, rotator cuff repairs, capsular shift or capsulolabral reconstructions, biceps tenodesis, deltoid repairs.

Foot and Ankle: Hallux valgus repairs, medial or lateral instability repairs/reconstructions, Achilles repairs/reconstructions, mid-foot reconstructions, metatarsal ligament repair.

Knee: Medial collateral ligament repair, lateral collateral ligament repair, posterior oblique ligament repair, Iliotibial band tenodesis, patellar tendon repair.

Hand/Wrist/Elbow: Scapholunate ligament reconstructions, ulnar or radial collateral ligament reconstructions, tennis elbow repair, biceps tendon reattachment..

**Equivalent Device:**

The KFx Tissue Fixation System is substantially equivalent to existing suturing devices cleared by the Food and Drug Administration. The KFx Medical Knotless Fixation System (K061294), the Arthrex Corkscrew FT II Suture Anchor (K050358), and the Arthrex FASTak II Suture Anchor (K971723) devices, are examples of substantially equivalent devices with the same intended use, design and technology characteristics requested by KFx Medical, Inc. The intended use of the KFx Tissue Fixation System is substantially equivalent to the intended use of the suturing devices listed above.

**Test Results:***Performance*

Results of physical bench testing demonstrate that the KFx Tissue Fixation System meets its specifications and does not raise new issues of safety or effectiveness.

*Biocompatibility*

The materials used in the KFx Tissue Fixation System are biocompatible. The same materials are used in the identified predicates and are also commonly used in similar medical devices.

**Summary:**

Based on the intended use, product, performance and biocompatibility information provided in this notification, the KFx Tissue Fixation System has been shown to be substantially equivalent to the currently marketed predicate devices.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

OCT 26 2007

KFx Medical  
% Mr. Malcolm D. Heaven  
Vice President Research and Development  
5145 Avenida Encinas, Suite C  
Carlsbad, California 92008

Re: K072063  
Trade Name: KFx Tissue Fixation System and Accessories  
Regulation Number: 21 CFR 888.3040  
Regulation Name: Smooth or threaded metallic bone fixation fastener  
Regulatory Class: Class II  
Product Code: MBI  
Dated: July 24, 2007  
Received: July 31, 2007

Dear Mr. Heaven:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Malcolm D. Heaven

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", with a stylized, flowing script.

Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

---

**Indications for Use**510(k) Number (if known): K072063

Device Name: KFX Tissue Fixation System and Accessories

**Indications for Use:**

The KFX Tissue Fixation System and optional accessories are intended for the fixation of soft tissue to bone in the shoulder, foot/ankle, knee, hand/wrist, and elbow.

**Specifically:**

Shoulder: Bankart lesion repairs, SLAP lesion repairs, acromio-clavicular separation repairs, rotator cuff repairs, capsular shift or capsulolabral reconstructions, biceps tenodesis, deltoid repairs.

Foot and Ankle: Hallux valgus repairs, medial or lateral instability repairs/reconstructions, Achilles repairs/reconstructions, mid-foot reconstructions, metatarsal ligament repair.

Knee: Medial collateral ligament repair, lateral collateral ligament repair, posterior oblique ligament repair, Iliotibial band tenodesis, patellar tendon repair.

Hand/Wrist/Elbow: Scapholunate ligament reconstructions, ulnar or radial collateral ligament reconstructions, tennis elbow repair, biceps tendon reattachment.

Prescription Use ✓  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF  
NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of General, Restorative,  
and Neurological Devices

Page \_\_ of \_\_